- ¥3bn
- ¥1bn
- ¥4bn
- 63
- 75
- 72
- 85
2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
Standards: | JAS | JAS | JAS |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 2,997 | 3,380 | 3,654 |
Cost of Revenue | |||
Gross Profit | 809 | 862 | 894 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Depreciation and Amortization | |||
Unusual Expense / Income | |||
Other Operating Expenses | |||
Total Operating Expenses | 2,563 | 2,949 | 3,227 |
Operating Profit | 433 | 431 | 427 |
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | 454 | 442 | 436 |
Provision for Income Taxes | |||
Net Income After Taxes | 314 | 303 | 290 |
Net Income Before Extraordinary Items | |||
Net Income | 314 | 303 | 290 |
Adjustments to Net Income | |||
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | 314 | 303 | 290 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | 157 | 157 | 146 |
Dividends per Share |